Imec is a world-leading R&D and innovation hub in nanoelectronics and digital technologies. At imec, we shape the future. How? By enabling nano- and digital technology innovation with a significant impact on the quality of life. With our partners from companies, governments and academia. And supported by the three pillars of our R&D: - a unique infrastructure that includes a 2.5-billion-euro 300mm semiconductor pilot line - more than 5,000 expert scientists from over 96 countries - an ecosystem of more than 600 world-leading industry partners and a global academic network Founded in 1984, imec quickly made its name as the …

Inspired by patients. Driven by science. UCB – Inspired by patients. Driven by science. At UCB, we put our heart, soul and skills into making a difference for people living with severe diseases. We look to transform patients’ lives by pushing the boundaries of what is possible. With us, our talents makes the most of who they are, unlocking innovation and setting new standards for patients. Everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” And to find the answers, we connect globally with patients and …

Because informed decisions lead to better outcomes As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders. Elsevier employs 8,700 people worldwide. We have supported the work of our research and health partners for more than 140 …

Sectors: Publishing

Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. With approximately 7000 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, …

Sectors: Biotechnology